Chu Clermont Ferrand
Clermont-Ferrand, 63003, France
NCT Number: NCT04174209
Keratoconus is a rare evolving corneal ectasia that alters visual acuity. To improve spectacle-corrected visual acuity, various subjective refraction techniques can be used.
The subjective refraction techniques of keratoconus-carrying patients have never been studied.
The main hypothesis is that the most suitable subjective ocular refraction method varies with the corneal topography of the keratoconus.
The main objective is to define the most appropriate refractive technique(s) based on corneal topographies in order to provide keratoconus-affected patients with the best spectacle-corrected visual acuity.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Clermont-Ferrand, 63003, France
Keratoconus is a rare evolving corneal ectasia that alters visual acuity. To improve spectacle-corrected visual acuity, various subjective refraction techniques can be used. The Jackson Cylinder Cross Method, the Astigmatic Dial Technique and the Stenopeic Slit are three validated subjective refraction techniques for measuring astigmatism. The subjective refraction techniques of keratoconus-carrying patients have never been studied.
The main hypothesis is that the most suitable subjective ocular refraction method varies with the corneal topography of the keratoconus.
The investigators collect several characteristics of corneal topography of the keratoconus : the average value of the keratometry of the 3 central mm called Km ; the value of the point corresponding to the maximum keratometry (called Kmax), the distance between the center and the point of Kmax, (called d_Kmax) ; the corneal surface variance index called ISV ; the Belin/Ambrósio Enhanced Ectasia Display (called BAD-D).
The main objective is to define the most appropriate refractive technique(s) based on corneal topographies in order to provide keratoconus-affected patients with the best spectacle-corrected visual acuity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients who receive the Jackson Cross Cylinder Method
Patients who receive the Astigmatic Dial Technique Method.
Patients who receive the Stenopeic slit Method.
Time frame: day 1
average value of the keratometry of the 3 central mm called Km
Time frame: day 1
value of the point corresponding to the maximum keratometry (called Kmax),
Time frame: day 1
Measure of the distance between the center and the point of Kmax, (called d_Kmax)
Time frame: day 1
measure of the corneal surface variance index called ISV
Time frame: day 1
Measure of the Belin/Ambrósio Enhanced Ectasia Display (BAD-D)
Time frame: day 1
Collection of the astigmatism axis given by each method, by the autorefractometer and by the corneal topography
Time frame: day 30
The need (yes / no) for the optician to modify the prescribed spectacle lens (due to poor tolerance)
Time frame: day 1
The impossibility (yes / no) of carrying out each of the 3 refraction methods.
Time frame: day 1
The values of the final corrective spheres (myopia or hyperopia).
University Hospital, Clermont-Ferrand
Other
Acronym: RE-CON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06818461
Corneal Diseases, Eye Diseases
Mohandessin, Giza Governorate, Egypt
View Trial DetailsNCT06100939
Corneal Diseases, Eye Diseases
Rowland Heights, California, United States
View Trial DetailsNCT06100952
Corneal Diseases, Eye Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT04418999
Allergy, Corneal Diseases
Chicago, Illinois, United States
View Trial Details